Tomonori Ishii

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

Dinesh Khanna, Celia J. F. Lin, Daniel E. Furst et al. · The Lancet Respiratory Medicine · 2020 · 652 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +4

Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)

Yoshikazu Nakaoka, Mitsuaki Isobe, Syuji Takei et al. · Annals of the Rheumatic Diseases · 2017 · 386 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +13

Human parvovirus B19 as a causative agent for rheumatoid arthritis

Yuichi Takahashi, Chihiro Murai, S Shibata et al. · Proceedings of the National Academy of Sciences · 1998 · 274 citations

Medicine, Immunology, Pathology +11

Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis

Shunsuke Furuta, Daiki Nakagomi, Y Kobayashi et al. · JAMA · 2021 · 217 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +14

Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection

Yasuhiko Munakata, Takako Saito‐Ito, Keiko Kumura-Ishii et al. · Blood · 2005 · 177 citations · Full text

Life Sciences, Immunology, Molecular Biology +15